Polyrizon Ends 2025 Debt-Free with $17.5M Cash, Advances Intranasal Programs
Polyrizon closed 2025 with $17.5 million in cash, no debt and full financial flexibility. The company advanced its intranasal pipeline with an FDA pre-submission meeting for PL-14, a Pre-RFD submission for PL-16, GMP manufacturing of trial materials and positive naloxone hydrogel preclinical results.
1. Year-End Financial Position
Polyrizon ended 2025 with approximately $17.5 million in cash and a debt-free balance sheet, providing strong financial flexibility to advance its clinical programs and explore strategic investments.
2. FDA Regulatory Progress
The company completed an FDA pre-submission meeting for the PL-14 allergy blocker to outline clinical development strategy and submitted a Pre-Request for Designation for the PL-16 viral blocker, setting the stage for future trial approvals.
3. Manufacturing and CRO Collaboration
GMP manufacturing of clinical trial material was secured through Eurofins CDMO, and a global preclinical CRO agreement was signed to initiate studies in Q2 2026, streamlining the path to human testing.
4. Preclinical Program Achievements
Positive preclinical data demonstrated enhanced nasal deposition and mucoadhesion for the intranasal naloxone hydrogel, while manufacturing upscaling for the nasal spray platform was completed and the PL-14 allergy blocker was branded NASARIX.